Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Only Private Industry Can Reach India's Rural Population As Government Focuses On Disease Prevention

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Trying to improve the quality of its healthcare services, India plans to reach out to its vast rural population while looking to create partnership opportunities within the private sector

You may also be interested in...



With No Big Push For R&D Or Infrastructure, Indian Budget Belies Pharma Industry Hopes

MUMBAI - The keenly watched "Union Budget" of the Indian government made no direct references or moves that could benefit the Indian pharmaceutical industry - leaving most senior level executives disappointed and hoping for progressive steps in the future

With No Big Push For R&D Or Infrastructure, Indian Budget Belies Pharma Industry Hopes

MUMBAI - The keenly watched "Union Budget" of the Indian government made no direct references or moves that could benefit the Indian pharmaceutical industry - leaving most senior level executives disappointed and hoping for progressive steps in the future

Indian Government Applauds 2010 Preventative Efforts That Lead To Drops In AIDS, Polio, TB

MUMBAI - India's Ministry of Health and Family Welfare has highlighted key indicators that point to an overall improvement in the quality and access of national health programs initiated over the past year

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC077212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel